0.8247
2.77%
0.0173
Lexicon Pharmaceuticals Inc stock is traded at $0.8247, with a volume of 249.51K.
It is up +2.77% in the last 24 hours and down -57.45% over the past month.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
See More
Previous Close:
$0.8074
Open:
$0.8043
24h Volume:
249.51K
Relative Volume:
0.08
Market Cap:
$311.01M
Revenue:
$1.21M
Net Income/Loss:
$-177.12M
P/E Ratio:
-1.2127
EPS:
-0.68
Net Cash Flow:
$-162.37M
1W Performance:
-21.72%
1M Performance:
-57.45%
6M Performance:
-50.31%
1Y Performance:
-23.17%
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Name
Lexicon Pharmaceuticals Inc
Sector
Industry
Phone
(281) 863-3000
Address
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Compare LXRX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
LXRX | 0.8263 | 311.01M | 1.21M | -177.12M | -162.37M | -0.68 |
VRTX | 448.31 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 744.75 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 589.91 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 249.68 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 102.52 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-07-23 | Initiated | Jefferies | Hold |
Aug-12-22 | Initiated | Piper Sandler | Overweight |
Jan-29-21 | Upgrade | JP Morgan | Underweight → Neutral |
Jan-29-21 | Downgrade | Wedbush | Outperform → Neutral |
Dec-08-20 | Upgrade | Citigroup | Neutral → Buy |
Nov-18-20 | Upgrade | Gabelli & Co | Hold → Buy |
Dec-11-19 | Downgrade | Gabelli & Co | Buy → Hold |
Nov-08-19 | Downgrade | Citigroup | Buy → Neutral |
Sep-11-19 | Upgrade | Gabelli & Co | Hold → Buy |
Jul-29-19 | Downgrade | Stifel | Buy → Hold |
Mar-25-19 | Upgrade | Gabelli & Co | Sell → Hold |
Jul-31-18 | Reiterated | Stifel | Buy |
Feb-23-18 | Downgrade | Needham | Buy → Hold |
Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
Mar-01-17 | Reiterated | H.C. Wainwright | Buy |
Mar-01-17 | Reiterated | Wedbush | Outperform |
Oct-07-16 | Initiated | H.C. Wainwright | Buy |
Aug-05-16 | Reiterated | Wedbush | Outperform |
Aug-02-16 | Initiated | Citigroup | Buy |
Mar-02-16 | Reiterated | Wedbush | Outperform |
Nov-09-15 | Reiterated | Wedbush | Outperform |
Sep-28-15 | Upgrade | Gabelli & Co | Sell → Hold |
Sep-18-15 | Downgrade | Gabelli & Co | Hold → Sell |
Aug-10-15 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Lexicon Pharmaceuticals Inc Stock (LXRX) Latest News
Lexicon Appoints Ivan Cheung to Board of Directors - citybiz
Lexicon Pharmaceuticals appoints Ivan Cheung to board - Investing.com India
Lexicon Pharma (LXRX) Appoints Ivan H. Cheung to its Board - StreetInsider.com
Lexicon Pharmaceuticals, Inc. Announces Board Changes - Marketscreener.com
Lexicon Pharmaceuticals (LXRX) Stock Plummets Amidst Market Acti - GuruFocus.com
Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week - Yahoo Finance
Leerink Partnrs Has Positive Estimate for LXRX Q4 Earnings - MarketBeat
Lexicon Pharmaceuticals stock hits 52-week low at $1 - Investing.com India
What is HC Wainwright's Forecast for LXRX FY2024 Earnings? - MarketBeat
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago - The Manila Times
Lexicon's Sotagliflozin Shows Strong Benefits Across All Heart Failure Stages in New Data | LXRX Stock News - StockTitan
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Q3 2024 Earnings Call Transcript - Insider Monkey
HC Wainwright Reaffirms Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Needham & Company LLC Reiterates Hold Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Demystifying Lexicon Pharmaceuticals: Insights From 10 Analyst Reviews - Benzinga
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlig - GuruFocus.com
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... - Yahoo Finance
Lexicon: Q3 Earnings Snapshot - The Washington Post
FMR LLC's Strategic Acquisition of Lexicon Pharmaceuticals Shares - GuruFocus.com
LXRXLexicon Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings: EPS of -$0. - GuruFocus.com
Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Lexicon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Previ - GuruFocus.com
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Report Preview: What To Look For - Yahoo Finance
Lexicon Pharmaceuticals (LXRX) to Release Quarterly Earnings on Tuesday - MarketBeat
Lexicon Pharmaceuticals to Participate in the Jefferies London Global Healthcare Conference - The Manila Times
Lexicon Pharmaceuticals CEO to Present at Jefferies London Healthcare Conference | LXRX Stock News - StockTitan
The Analyst Landscape: 11 Takes On Lexicon Pharmaceuticals - Benzinga
HC Wainwright Reiterates Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024 - The Manila Times
Pharma Stock Has Significant Upside Potential, Analyst Says - Streetwise Reports
Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss - StockTitan
Lexicon Pharmaceuticals (NASDAQ:LXRX) Given “Hold” Rating at Needham & Company LLC - Defense World
Lexicon Pharmaceuticals Loses Over A Third Of Its Market Cap Post FDA Vote On Drug: Retail Sentiment Sours - MSN
FDA panel vote leaves Lexicon’s Zynquista hopes hanging by a thread - The Pharma Letter
Lexicon stock in selloff on FDA AdCom rebuke (LXRX:NASDAQ) - Seeking Alpha
Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote - MarketWatch
Lexicon Pharmaceuticals (LXRX) PT Lowered to $5 at Leerink Partners - StreetInsider.com
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease - The Manila Times
FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes - Reuters.com
FDA advisers vote against Lexicon Pharma’s add-on drug for type 1 diabetes - PharmaLive
Lexicon’s Zynquista: Negative Adcomm Vote In Type 1 Diabetes Includes Support For Revised Indication - Citeline News & Insights
Lexicon Pharmaceuticals Halted All Day as FDA Panel Reviews Zynquista - MarketWatch
Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista -- Update - MarketWatch
Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista — Update - Morningstar
Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista - Morningstar
Lexicon Pharmaceuticals Inc Stock (LXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):